-
1
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
Published 2025-01-01“…Translational Neurodegeneration…”
Get full text
Article -
2
Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy
Published 2025-02-01“…Translational Neurodegeneration…”
Get full text
Article -
3
Inflammasomes in neurodegenerative diseases
Published 2024-12-01“…Translational Neurodegeneration…”
Get full text
Article -
4
Correction: CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation
Published 2025-01-01“…Translational Neurodegeneration…”
Get full text
Article -
5
Correction: Inflammasomes in neurodegenerative diseases
Published 2025-01-01“…Translational Neurodegeneration…”
Get full text
Article -
6
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease
Published 2025-01-01“…Translational Neurodegeneration…”
Get full text
Article -
7
Peripheral proteinopathy in neurodegenerative diseases
Published 2025-01-01“…Translational Neurodegeneration…”
Get full text
Article -
8
CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation
Published 2024-12-01“…Translational Neurodegeneration…”
Get full text
Article -
9
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology
Published 2025-01-01“…Translational Neurodegeneration…”
Get full text
Article